Please assess the completion status of the following clinical trial:

Trial Title: Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years,~* has tinnitus~Exclusion Criteria:~* Pacemaker,~* pregnancy,~* metal implants in head or neck,~* thrombosis, migraines/headaches,~* metal bonded retainer, surgeries within the last 6 months which patient is still recovering from,~* any medical reason your physician would advise against the use of this device,~* under 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tinnitus (Type: EXPERIMENTAL): Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device.
- No tinnitus (Type: NO_INTERVENTION): Individuals without tinnitus will also be masked with the device.

Based on this trial design, predict the completion outcome and termination type (if applicable).